EIF2B2 Antibody

Code CSB-PA007515GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
EIF2B2
Alternative Names
EI2BB_HUMAN antibody; EIF 2Bbeta antibody; EIF-2Bbeta antibody; EIF2B antibody; EIF2B GDP GTP exchange factor subunit beta antibody; EIF2B2 antibody; EIF2B2 antibody antibody; EIF2BB antibody; Eukaryotic translation initiation factor 2B antibody; Eukaryotic translation initiation factor 2B beta antibody; Eukaryotic translation initiation factor 2B; subunit 2 antibody; Eukaryotic translation initiation factor 2B; subunit 2 beta antibody; Eukaryotic translation initiation factor 2B; subunit 2 beta; 39kDa antibody; S20I15 antibody; S20III15 antibody; Translation initiation factor eIF-2B subunit beta antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Human EIF2B2
Immunogen Species
Homo sapiens (Human)
Isotype
IgG
Purification Method
Antigen Affinity Purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
ELISA,WB,IHC
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP.
Gene References into Functions
  1. Data show that eIF2Balpha and eIF2Bbeta bind to adjacent surfaces on eIF2alpha-N-terminal domains (NTDs). PMID: 29036434
  2. It would be better to consider Vanishing White Matter Disease as an eIF2B-related multisystem disorder, not just as a neurological disorder. PMID: 28041799
  3. An Italian patient is described with a c.638A>G mutation in exon 5 of EIF2B2 gene with very slow progressive vanishing white matter disease. PMID: 22729508
  4. analysis of vanishing white matter disease caused by EIF2B2 mutation with the presentation of an adrenoleukodystrophy phenotype [case report] PMID: 22285377
  5. Mutation in EIF2B2 causes childhood ataxia with central nervous system hypomyelination/ vanishing white matter leukodystrophy. PMID: 12707859
  6. Biochemical analyses indicate that mutations analyzed in eIF2Balpha and -epsilon reduce the steady-state level of the affected subunit, while the most severe mutant tested, eIF2Bbeta(V341D), forms complexes with reduced stability and lower eIF2B activity. PMID: 14993275
  7. The role of the residues Ser2 and Ser67 contribute to the important role of the N-terminal region of eIF2beta for its function in mammals. PMID: 16225457
  8. CACH syndrome is linked to mutations in the five EIF2B--REVIEW PMID: 17878805
  9. Study reports 9 novel mutations in EIF2B genes in 8 patients, increasing number of known mutations to >120. Using homology modeling, analyzed the impact of novel mutations on the 5 subunits of eIF2B protein (alpha, beta, gamma, delta, epsilon). PMID: 18263758

Show More

Hide All

Involvement in disease
Leukodystrophy with vanishing white matter (VWM)
Protein Families
EIF-2B alpha/beta/delta subunits family
Database Links

HGNC: 3258

OMIM: 603896

KEGG: hsa:8892

STRING: 9606.ENSP00000266126

UniGene: Hs.409137

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*